Page 2, amend the third full paragraph (beginning at line 7, shown as line 10 on the page) as follows:

The neurotrypsin of the human (compound of the formula I, SEQ ID NO: 1) has a coding sequence of 2625 nucleotides. The coded peptide of the compound of the formula I (SEQ ID NO: 1) has a length of 875 amino acids and contains a signal peptide of 20 amino acids (SEQ ID NO: 2). The neurotrypsin of the mouse (compound of the formula II, SEQ ID NO: 3) has a length of 761 amino acids and contains a signal peptide of 21 amino acids (SEQ ID NO: 4). The reason for the greater length of the neurotrypsin of the human consists therein that the human neurotrypsin has 4 SRCR domains, whereas the neurotrypsin of the mouse has only 3 SRCR domains.

C2

Page 3, amend the first full paragraph after the sequences, (shown as lines 2-5 on the page) as follows:

From the 258 amino acid sequence positions included in the comparison there are 233 amino acids that are identical in both compounds (upper sequence: compound of the formula I, SEQ ID NO: 1; lower sequence: compound of the formula II, SEQ ID NO: 3; identical amino acids are indicated by vertical lines).

C3

Page 7, amend the depiction of the sequences after the first full paragraph (after line 13, shown as line 15 on the page) as follows:



					SEQ ID NOS:
tPA (m)	..SSC	W V L S A A H C	FLE.....HDA	C Q G D S G G	PLV..	9, 10
uPa (m)	..SPC	W V A S A A H C	FIQ.....TDS	C K G D S G G	PLI..	11, 12
thrombin (m)	..SDR	W V L T A A H C	ILY.....GDA	C E G D S G G	PFV..	13, 14
plasmin (m)	..APE	W V L T A A H C	LKS.....VDS	C Q G D S G G	PLV..	15, 16
trypsin (m)	..NDQ	W V V S A A H C	YKY.....KDS	C Q G D S G G	PVV..	17, 18
chymTryp b (r)	..SED	W V V T A A H C	GVK.....VSS	C M G D S G G	PLV..	19, 20
pancElas II (m)	..ANN	W V L T A A H C	LSN.....TSS	C N G D S G G	PLN..	21, 22

Primer (I) 5'-TGG GTI SYI WSI GCI GCI CAT TG-3' (SEQ ID NO: 7) (II) 3'-ACR BTY CCI CTR WSI CCI CC-5' (SEQ ID NO: 8)

Page 8, amend the first full paragraph (lines 1-5) as follows:

The following primers were used:

In the reading direction (sense primers; SEQ ID NO: 23):

5'-GGGGAATTCTGGGTI(C/G)(T/C)I(T/A)(G/C)IGCIGCICA(T/C)TG-3'

In the counter direction (antisense primers; SEQ ID NO: 24):

5'-GGGGGATCCCCICCI(G/C)(A/T)(A/G)TCICC(C/T)T(G/C/T)(G/A)CA-3'.

Page 10, amend the text after first full paragraph (lines 10-13) as follows:

In the reading direction (sense primers; SEQ ID NO: 25):

5'-GGGAAGCTTGGICA(A/G)TGGGGIACI(A/G)TITG(C/T)GA(C/T)-3'

C6 In the counter direction (antisense primers; SEQ ID NO: 26):

5'-GGGCTCGAGCCCCAICCTGTTATGTAAIAGTTG-3'.

Page 12, amend the first full paragraph as follows:

The more than 60 amino acids long proline-rich, basic segment at the amino terminus of the coded sequence of the compounds of the formulas I and II is well suited for the production of antibodies by means of synthesizing peptides and using them for immunization. We have selected two peptide sequences with a length of 19 and 13 amino acids from the C7 proline-rich, basic segment at the amino terminus of the coded sequence of the compound of the formula II for the generation of antibodies. The peptides had the following sequences:

Peptide 1 (SEQ ID NO: 27): H_2N-SRS PLH RPH PSP PRS QX-$CONH_2$

Peptide 2 (SEQ ID NO: 28): H_2N-LPS SRR PPR TPR F-COOH